Analysts expect Disc Medicine, Inc. to report revenue of 0.00 for Q3 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - |
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 486,502.47 | 0.00 | 0.00 | 0.00 | 0.00 | 588,450.97 |
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 444,926.29 | 0.00 | 0.00 | 0.00 | 0.00 | 533,680.83 |
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 465,714.38 | 0.00 | 0.00 | 0.00 | 0.00 | 561,065.90 |
Analysts expect Disc Medicine, Inc. to report earnings per share of -1.63 for Q3 26, against a range of -1.73 to -1.53. The most recent reported quarter, Q2 26, came in at -1.54, a 4.9% beat against the -1.62 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.89 | -0.95 | -1.02 | -1.58 | -1.77 | -1.64 | -1.65 | -1.54 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.95 | -1.01 | -1.12 | -1.05 | -1.23 | -1.54 | -1.53 | -1.53 | -1.53 | -1.71 | -1.85 | -1.66 | -1.96 | -1.74 | -1.35 | -1.20 | ||||||||||
| Low Estimate | -1.07 | -1.13 | -1.22 | -1.13 | -1.49 | -1.72 | -1.85 | -1.71 | -1.73 | -1.97 | -2.01 | -2.00 | -2.12 | -1.94 | -1.47 | -1.34 | ||||||||||
| Consensus Estimate | -1.01 | -1.07 | -1.17 | -1.09 | -1.36 | -1.63 | -1.69 | -1.62 | -1.63 | -1.84 | -1.93 | -1.83 | -2.04 | -1.84 | -1.41 | -1.27 |